Physician profile
Charles E Laurence
NPI 1285641001
$4,447.66
in general payments reported to CMS, 2019-2025
25 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $1,189 · 2021: $682 · 2022: $185 · 2023: $267 · 2024: $623 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,304.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $644.09 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $424.24 | 2019-2022 | |
| Amgen INC. | $359.61 | 2019-2024 | Otezla, Repatha, Evenity |
| Allergan, INC. | $351.12 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.69 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Novartis Pharmaceuticals Corporation | $152.31 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $130.18 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $129.11 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $63.93 | 2020 | |
| Astellas Pharma US INC | $59.81 | 2019-2021 | |
| Pfizer INC. | $59.20 | 2019-2024 | |
| Abbvie INC. | $54.62 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.92 | 2019-2024 | Xifaxan |
| Mannkind Corporation | $53.09 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $46.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $38.71 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.22 | 2024 | |
| Janssen Pharmaceuticals, INC | $32.88 | 2019 | |
| Eisai INC. | $19.65 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $19.03 | 2023 | Spritam |
| Genentech USA, INC. | $18.25 | 2019 | |
| Exact Sciences Corporation | $17.17 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $15.96 | 2019 | |
| Glaxosmithkline, LLC. | $14.28 | 2024 | Arexvy, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Laurence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.